HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

AuthorsS Rule, W Jurczak, M Jerkeman, C Rusconi, M Trneny, F Offner, D Caballero, C Joao, M Witzens-Harig, G Hess, I Bence-Bruckler, S-G Cho, C Thieblemont, W Zhou, T Henninger, J Goldberg, J Vermeulen, M Dreyling
JournalLeukemia (Leukemia) Vol. 32 Issue 8 Pg. 1799-1803 (08 2018) ISSN: 1476-5551 [Electronic] England
PMID29572505 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • temsirolimus
  • Adenine
  • Sirolimus
Topics
  • Adenine (analogs & derivatives)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Follow-Up Studies
  • Humans
  • International Agencies
  • Lymphoma, Mantle-Cell (drug therapy, pathology)
  • Piperidines
  • Prognosis
  • Pyrazoles (administration & dosage)
  • Pyrimidines (administration & dosage)
  • Salvage Therapy
  • Sirolimus (administration & dosage, analogs & derivatives)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: